Katherine Singson New CEO of Volpara Solutions

Katherine Singson has been hired as the new CEO of Volpara Solutions.

Katherine Singson role will be to drive continued growth for Volpara’s breast cancer detection and patient tracking software. With 30+ years of experience from start-ups to multinationals including NeXT/Apple®, Pixar® and Microsoft®, Katherine brings both business-to-business as well as direct-to-consumer experience to this crucial new role.

After being mentored by Steve Jobs at all three of his companies, she spent several years abroad including in Sydney, Australia.  A highlight of this time overseas was working at Microsoft ANZ (Australia & New Zealand) where she partnered with Oprah Winfrey’s Ultimate Australian Adventure* to showcase both Windows and Xbox in a deeply humanistic manner.  Katherine is also a recent breast cancer survivor.

Volpara combines artificial intelligence, physics and data to measure breast density for early detection of cancer as well as the clinical management of images. Nearly half of women in the US have dense breast tissue.  Objective breast density analysis can help clinicians and their patients create a plan for ongoing screening based on each woman’s individual risk factors.  Additionally, Volpara’s software provides quality control for mammography centers and patient tracking software.

“As a purpose-driven technology company with the potential to transform the future of breast cancer, we’re excited to have someone of Katherine’s experience unleash our potential,” said Dr. Ralph Highnam, Founder and New Zealand-based Group CEO. “Volpara is already working with luminary customers across the US, including renowned sites in New York, Houston, San Francisco, Austin, Charlotte and Seattle, and of course, we want to reach many more. We look forward to Katherine positively impacting the healthcare industry and seeing how she’ll no doubt tap into the power and passion of women to obliterate advanced-stage breast cancer.”

“In these uncertain times, we aim to create a nimble, responsive and tastefully relentless approach to addressing this destructive disease,” said Katherine. “Since Covid-19, the idea of actively participating in one’s own self-care in partnership with leading-edge healthcare providers is stronger than ever.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”